The effect of neonatal gene therapy with a gamma retroviral vector on cardiac valve disease in mucopolysaccharidosis VII dogs after a decade

Mucopolysaccharidosis VII (MPS VII) is due to deficient activity of the lysosomal enzyme β-glucuronidase (GUSB) and results in the accumulation of glycosaminoglycans (GAGs). This study determined the long-term effect of neonatal intravenous injection of a gamma retroviral vector (RV) on cardiac valv...

Full description

Saved in:
Bibliographic Details
Published in:Molecular genetics and metabolism 2013-11, Vol.110 (3), p.311-318
Main Authors: Bigg, Paul W., Sleeper, Meg M., O'Donnell, Patricia A., Liu, Yuli, Wu, Susan, Casal, Margret L., Haskins, Mark E., Ponder, Katherine P.
Format: Article
Language:English
Subjects:
Animals
Animals, Newborn
Aortic Valve - diagnostic imaging
Aortic Valve - pathology
Cardiac disease
Disease Models, Animal
Dogs
Echocardiography
Female
Gammaretrovirus - genetics
Gene therapy
Genetic Therapy
Genetic Vectors - genetics
Glucuronidase - genetics
Glucuronidase - metabolism
Heart Valve Diseases - diagnostic imaging
Heart Valve Diseases - etiology
Heart Valve Diseases - therapy
Lysosomal storage disease
Male
Mitral Valve - diagnostic imaging
Mitral Valve - pathology
Mucopolysaccharidosis
Mucopolysaccharidosis VII - complications
Mucopolysaccharidosis VII - genetics
Retroviral vector
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mucopolysaccharidosis VII (MPS VII) is due to deficient activity of the lysosomal enzyme β-glucuronidase (GUSB) and results in the accumulation of glycosaminoglycans (GAGs). This study determined the long-term effect of neonatal intravenous injection of a gamma retroviral vector (RV) on cardiac valve disease in MPS VII dogs. Transduced hepatocytes secreted GUSB into the blood for up to 11years at levels similar to or greater than those achieved with enzyme replacement therapy (ERT). Valve regurgitation and thickening were scored from 0 (normal) to +4 (severely abnormal). At 1year, untreated MPS VII dogs had mitral regurgitation, mitral valve thickening, aortic regurgitation, and aortic valve thickening scores of 2.3±0.7, 2.3±0.6, 1.8±0.5, and 1.6±0.7, respectively, which were higher than the values of 0.6±0.1, 0.1±0.4, 0.3±0.8, and 0.1±0.4, respectively, in treated MPS VII dogs. Treated MPS VII dogs maintained low aortic regurgitation and aortic valve thickening scores in their lifetime. Although mitral regurgitation and mitral valve thickening scores increased to 2.0 at ≥8years of age in the treated MPS VII dogs, older normal dogs from the colony had similar scores, making it difficult to assess mitral valve disease. Older treated dogs had calcification within the mitral and the aortic valve annulus, while GUSB staining demonstrated enzyme activity within the mitral valve. We conclude that neonatal RV-mediated gene therapy reduced cardiac valve disease in MPS VII dogs for up to 11years, and propose that neonatal initiation of ERT should have a similar effect. •Neonatal gene therapy reduces mitral valve disease in MPS VII dogs for 7years.•Neonatal gene therapy reduces aortic valve disease in MPS VII dogs for 11years.•Results predict that initiation of ERT at birth will reduce heart disease long-term.
ISSN:1096-7192
1096-7206
DOI:10.1016/j.ymgme.2013.06.015